November 13, 2015Current Opinion in Lipidology
Novel therapeutics in hypertriglyceridemia
Key result
Novel TG-lowering therapies show biochemical efficacy but lack long-term clinical outcome data.
Why the study?
Recent advances in therapies for hypertriglyceridemia, including novel agents for familial chylomicronemia and other lipid disorders, require summarization to inform clinical practice.
Population
Patients with familial chylomicronemia, hypertriglyceridemia, and other lipid disorders
Design
Review article
Authors
Discussion
Loading...
Member takes
Implication
Biochemical promise of new agents should not yet alter practice; leaves open the need for cardiovascular outcome trials.
Structured PICO
P
Population
Patients with hypertriglyceridemia, familial chylomicronemia syndrome, and other lipid disorders
I
Intervention
Novel triglyceride-lowering therapies including alipogene tiparvovec, mipomersen, volanesorsen, lomitapide, pradigastat, REGN1500, omega-3 fatty acids, and PPAR agonists
Novel therapeutics for hypertriglyceridemia show promising biochemical efficacy, particularly for severe cases like familial chylomicronemia syndrome, but require further long-term clinical outcome data.
Limitations
- Data on long-term clinical outcomes are still limited
- Cost will be an important consideration, likely restricting use to orphan indications
- Limited data on long-term clinical outcomes
- Cost considerations may restrict use to orphan indications
Cite This Study
Gryn et al. (2015) conducted a review in Hypertriglyceridemia. Novel triglyceride-lowering therapies was evaluated. Several promising triglyceride-lowering therapies are in development with good biochemical efficacy, though long-term clinical outcome data remain limited.